luliconazole

General

Pronunciation:
loo-li-kon-a-zole


Trade Name(s)

  • Luzu

Ther. Class.
antifungals

Pharm. Class.
azoles

Indications

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action

  • Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
  • Antifungal action .

Therapeutic Effect(s):

Resolution of dermal fungal infection.

Spectrum:

Active against Trichyphyton rubrum and Epidermpophyton floccosum.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.

Distribution: Unknown.

Protein Binding: >99%

Metabolism and Excretion: Unknown.

Half-life: Unknown.

TIME/ACTION PROFILE (improvement/resolution of infection)

ROUTEONSETPEAKDURATION
topicalunknown3–4 wk†unknown
†Following initiation of treatment.

Contraindication/Precautions

Contraindicated in:

  • None noted.

Use Cautiously in:

  • OB: Lactation:Safety not established;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Derm: application site reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

May inhibit the activity of the CYP2C19 enzymes.

Route/Dosage

Topical: (Adults) Interdigital tinea pedis Apply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporis Apply to affected and surrounding areas once daily for one week.

Availability

Cream: 1%

Assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Diagnoses

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
    • For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
    • Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
  • Patients with athlete's foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in skin irritation and resolution of infection.

luliconazole is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - luliconazole ID - 110104 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110104/all/luliconazole PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -